Ua hoʻolaha ʻo Juniper Biologics i kēia lā ua loaʻa iā ia nā kuleana laikini e hoʻomohala a kūʻai aku i ka TG-C LD (TissueGene-C haʻahaʻa haʻahaʻa) no ka mālama ʻana i ka osteoarthritis kuli.

ʻO ka $600 miliona USD laikini laikini e uhi ana iā Asia Pacific, Middle East a me ʻApelika i pūlima ʻia me Kolon Life Science a ʻo ia ka lua o ka loaʻa ʻana o Juniper Biologics i nā mahina he nui. Ma lalo o nā ʻōlelo o ka hui, ʻo Juniper Biologics ke kuleana no ka hoʻomohala ʻana a me ka hoʻolaha ʻana i ka TG-C LD i nā limahana lapaʻau a me nā halemai i loko o kēia mau wahi. Na Kolon Life Science ke kuleana no ke kākoʻo ʻana i ka hoʻomohala ʻana a me ka hāʻawi ʻana iā TG-C LD.

ʻO TG-C LD kahi lāʻau noiʻi non-surgical i hoʻomaikaʻi ʻia ʻo ia ka lāʻau lapaʻau mua o ka cell-mediated gene therapy no ka osteoarthritis o ke kuli, [i] ʻo ia ka ʻano maʻamau o ka arthritis.[ii] Wahi a ka noiʻi, osteoarthritis Ua manaʻo ʻia ʻo ia ka ʻumikūmākahi [1] kumu nui o ke kīnā ma ka honua holoʻokoʻa me ka 300 miliona mau maʻi ma Asia Pacific a me Middle East a me ʻApelika wale nō, e loaʻa ana i nā hopena nāwaliwali o ka maʻi hui degenerative. ʻO ia kekahi o nā pono olakino nui ʻole i hoʻokō ʻia ma waena o nā kūlana musculoskeletal me ka pilikia i hōʻike ʻia e piʻi me ka makahiki[iii].

ʻO kahi lāʻau lapaʻau mua i loko o ka papa cell-mediated gene therapy, ʻo TG-C LD ka mea i hoʻopaʻa ʻia i ka osteoarthritis o ke kuli ma o kahi hoʻokahi intra-articular injection. ʻO Kolon TissueGene, ka mea paʻa laikini no TG-C ma ʻAmelika Hui Pū ʻIa (ʻaʻole TG-C LD), ua hoʻopau ʻo ia i kahi hoʻokolohua lapaʻau ʻo 2 ma ʻAmelika Hui Pū ʻIa, me ka ʻikepili mua e hōʻike ana i ka hoʻomaha ʻana i ka ʻeha a me ka hoʻomaikaʻi ʻana o ka neʻe ʻana ma hope o hoʻokahi injection. ka hui kuli, no 2 makahiki paha. Ke hoʻomau nei nā hoʻokolohua lapaʻau Phase 3 ma ʻAmelika Hui Pū ʻIa me 1,020 mau mea maʻi e hōʻoia i ka palekana a me ka pono o TG-C. Ma waho aʻe o ka hōʻoia ʻana i ka hōʻemi nui o ka ʻeha a me ka hoʻomaikaʻi ʻana i ka hana i ʻike ʻia mai ka US Phase 2 clinical trial, ua hoʻolālā ʻia nā hoʻāʻo e hōʻike i ka lohi o ka piʻi ʻana o ka maʻi e hoʻokō i kahi inoa DMOAD (Disease Modifying Osteoarthritis Drug).

ʻO Juniper Biologics CEO, Raman Singh, i ʻōlelo: "Ke ʻimi mau nei mākou e ʻike i nā wahi e hiki ai iā mākou ke hana i ka ʻokoʻa loa a hāʻawi ʻo TG-C LD i kahi hōʻoluʻolu nui no nā poʻe maʻi osteoarthritis o ke kuli i makemake ʻia i ke ʻoki a i ʻole nā koho ʻē aʻe. Hoʻopaʻa mākou i ka hāʻawi ʻana i nā lāʻau lapaʻau hou e mālama i ka osteoarthritis o ke kuli ma o ka hoʻolaʻa hou ʻana o ka cartilage a ke manaʻoʻiʻo nei mākou e lawe mai kēia ʻano hana hoʻokolokolo hou i ka hōʻoluʻolu i nā miliona o nā maʻi ma ka ʻāina.

"ʻOliʻoli mākou e hana pū me Juniper Biologics e hoʻokumu i nā ala hou no nā poʻe maʻi e komo i kēia ʻano hoʻokolohua hoʻokolohua cell therapy. He hōʻoia kēia o kā mākou ʻenehana a me kāna waiwai mākeke, "wahi a Woosok Lee Pelekikena a me Luna Nui, Kolon Life Science. "Ke manaʻoʻiʻo nei mākou e hiki i nā poʻe maʻi ma Asia Pacific, Middle East a me ʻApelika ke pōmaikaʻi mai ka TG-C LD i ko mākou hele ʻana i ka paʻakikī o ka hoʻokumu ʻana i kahi koho lapaʻau maʻamau honua."

He aha e lawe ʻia mai kēia ʻatikala:

Kolon TissueGene, the license holder for TG-C in the United States (not TG-C LD), has already completed a phase 2 clinical trial in the United States, with initial data demonstrating sustained pain relief and mobility improvement following a single injection in the knee joint, for possibly up to 2 years.
TG-C LD is a non-surgical investigational treatment that has been hailed as the world’s first cell-mediated gene therapy for osteoarthritis of the knee,[i] which is the most common form of arthritis.
“We believe patients in Asia Pacific, Middle East and Africa will be able to benefit from TG-C LD as we go through the rigor of establishing it as a global standard treatment option.